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Abstract
It was previously shown that the 99mTc-labeled hydrazinonicotinamide (HYNIC)-conjugated LTB4 antagonist MB81 visualized infectious
foci in rabbits adequately and within a few hours after injection. Here, the bivalent HYNIC-conjugated LTB4 antagonist MB67 (analog of
MB81) was fluorinated with 18F via hydrazone formation and tested in vivo.
Methods: MB67 was [18F]-fluorinated via reaction of the [18F]-fluorinated intermediate p-[18F]-fluorobenzaldehyde ([18F]FB) and the
HYNIC moiety of MB67 via hydrazone formation. For comparison, MB67 was also labeled with 99mTc. The biodistribution of 18F- and
99mTc-labeled MB67 was investigated in rabbits with intramuscular infection.
Results: [18F]-MB67 was obtained at a maximum specific activity of 1200 GBq/mmol and proved to be stable in phosphate buffered saline
(PBS) at 37°C for at least 4 h. PET images obtained with [18F]-MB67 clearly delineated the abscess at 2 and 4 h pi. Counting of dissected
tissues at 4 h pi revealed an abscess uptake of 0.073±0.005 %ID/g, as compared to 0.160±0.010 %ID/g for the 99mTc-labeled analog.
Abscess-to-muscle ratios were 23±4 for [18F]-MB67 and 35±9 for [99mTc]-MB67.
Conclusion: The present study showed the feasibility of a new [18F]-labeling methodology and its application in the production of a new
PET tracer for imaging of infection, [18F]-MB67.
© 2007 Elsevier Inc. All rights reserved.
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1. Introduction
In previous studies, we demonstrated that the 99mTc-
labeled hydrazinonicotinamide (HYNIC)-conjugated leuko-
triene B4 (LTB4) antagonists MB88 (monovalent) and
MB81 (bivalent) were potent and promising agents for
SPECT imaging of infection and inflammation [1]. The
LTB4 receptor is expressed on polymorphonuclear granulo-
cytes and is involved in leukocyte function during the
inflammatory response. These agents revealed infectious
foci in rabbits adequately as early as 2 h pi. The rapid
pharmacokinetics of these agents prompted us to investigate
the potential of [18F]-fluorinated LTB4 antagonists for PET
imaging of infection and inflammation. 18F is the most
commonly used radionuclide for PET and has a half-life of
nearly 2 h. PET is rapidly gaining worldwide acceptance and
offers distinct advantages over SPECT with 99mTc with
respect to image resolution and the accuracy to quantify
uptake. In the present study, we applied a new [18F]-labeling
methodology to [18F]-fluorinate, the HYNIC-conjugated
LTB4 antagonist MB67 (analog of MB81), a nonpeptide
compound (Fig. 1). The methodology is based on the
reaction of an aldehyde, p-[18F]fluoro-benzaldehyde ([18F]
FB), with the HYNIC moiety of a reagent via hydrazone
formation. Applications of this new technology were shown
for [18F]-labeling of human serum albumin [2], c(RGDyK)
[3], for octreotide and for substance-P [4]. The technology to
label peptides and proteins with 99mTc via HYNIC as
adopted extensively by our group [1,5–8] was transformed
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here to a fluorination technology. Results of [18F]-fluori-
nated MB67 were compared to results obtained with 99mTc-
labeled MB67 in rabbits with soft tissue infection.
2. Methods
The HYNIC-conjugated LTB4-receptor antagonist
MB67 (Fig. 1) is a derivative of MB81 (BMS57868-
81), the synthesis of which has been described in detail
elsewhere [9]. MB67 is a bivalent LTB4 antagonist
consisting of two identical LTB4 receptor-binding moi-
eties, each modified with tetra-cysteic acid. The LTB4-
binding moieties are joined using the carboxyl groups of
glutamic acid and conjugated with HYNIC. In the case of
MB81, the hydrazine moiety of HYNIC was protected by
formation of a hydrazone with benzaldehyde; in the case
of MB67, the hydrazine moiety was converted into a
hydrazone by reaction with propylaldehyde. The propyl-
hydrazone contributes to long-term stability and is
Fig. 1. Chemical structure of HYNIC-LTB4-receptor antagonist MB67 and reaction with [18F]FB (Reaction A) and 99mTcO4
− in the presence of coligands tricine
and isonicotinic acid (Reaction B).
692 H.J.J.M. Rennen et al. / Nuclear Medicine and Biology 34 (2007) 691–695
converted into the kinetically favored hydrazone formed
in the reaction with [18F]FB.
2.1. Radiolabeling
2.1.1. Synthesis of [18F]FB
The synthesis of the unlabeled precursor of [18F]FB,
p-trimethylammoniumbenzaldehyde triflate, was performed
according to Haka et al. [10]. No-carrier-added [18F]-fluoride
(2–3.5 GBq), on a Sep-Pak ion-exchange QMA cartridge
(Waters, Etten-Leur, The Netherlands), was obtained from
Cyclotron BV (Amsterdam, The Netherlands). The [18F]-
fluoride was eluted from the QMA cartridge into a 5-ml
reaction vial (Reacti-Vial, Pierce, Rockford, IL, USA) using
800 μl of acetronitrile containing 20 mg of Kryptofix 2.2.2.
(Merck, Darmstadt, Germany) and 50 μl 1 M potassium
carbonate in water. The solvent was evaporated under a
stream of nitrogen at 90°C. The [18F]-fluoride cryptate
solution was dried azeotropically three times with 250-μl
portions of dry acetronitrile.
To the dried [18F]-fluoride cryptate, 8 mg of the triflate
salt of p-trimethylammoniumbenzaldehyde in 500 μl of
dimethylsulfoxide was added. The vial was closed and
heated at 120°C. After 10 min, the vial was cooled to
room temperature and 3 ml of water was added. A cation
exchange SCX cartridge (Alltech, Breda, The Netherlands)
and a Sep-Pak C18 cartridge (Waters) were precondi-
tioned. The SCX cartridge was used to trap unreacted
p-trimethylammoniumbenzaldehyde and the Sep-Pak C18
cartridge was used to immobilize [18F]FB. The reaction
mixture was applied onto the cartridges (connected in
series), and the cartridges were washed extensively with
15 ml of water. The SCX cartridge was removed and [18F]
FB was eluted in 0.15-ml fractions from the Sep-Pak C18
cartridge with 1.5 ml of methanol. Fractions with the
highest concentrations of [18F]FB were pooled and used
for subsequent reactions with HYNIC-conjugated LTB4-
receptor antagonist MB67 as described in the next
paragraph. Aliquots were analyzed on RP-HPLC. An
Agilent 1100 series LC system (Agilent Technologies, Palo
Alto, CA, USA) equipped with an in-line NaI crystal
radiodetector (Raytest, Straubenhardt, Germany) was used
for analytical reversed-phase HPLC. An Alltima C18
column (5 μm, 4.6×250 mm, Alltech) was used at a flow
rate of 1 ml/min. Solvent A=10 mM ammonium acetate
pH 7.2; solvent B=100% acetonitrile. Gradient: 95%
Solvent A, 5% Solvent B from 0 to 5 min; 5–100%
Solvent B in 15 min; 100% solvent B for 5 min. In this
system, the retention time of [18F]FB was 18.2 min.
2.1.2. Labeling of HYNIC-conjugated LTB4 antagonist
MB67 with [18F]FB
For in vivo animal studies, a methanolic aliquot of 120 μl
[18F]FB (600 MBq) was reacted with 400 μg (=140 nmol) of
HYNIC-conjugated LTB4 antagonist MB67 in 120 μl of
0.4 M sodium acetate pH 4.2. The reaction was carried out at
50°C for 30 min. The conjugation efficiency was determined
by RP-HPLC. To terminate the labeling reaction, an equal
volume of 0.5 M phosphate buffer pH 7.4 was added to the
reaction mixture. [18F]FB was separated from [18F]-MB67
by coevaporation of methanol and [18F]FB at 50°C under a
stream of nitrogen. The stability of the purified [18F]-MB67
preparation in phosphate buffered saline (PBS) was
monitored at 37°C for 4 h by HPLC.
18F-Fluorinated MB67 was tested in a rabbit model of
Escherichia coli-induced focal intramuscular infection [5,8].
Four rabbits were injected with 40 MBq [18F]-MB67
(100 μg) via the lateral ear vein. Prior to imaging, the
rabbits were catheterized to void the bladder. Two rabbits
were immobilized, placed side by side on the PET scanner
(ECAT-EXACT, Siemens/CTI, Knoxville, TN, USA), and
images were recorded in 3D mode at 2 and 4 h pi. For
comparison, three rabbits with an E. coli-induced intramus-
cular infection received 5 MBq of 99mTc-labeled MB67.
MB67 was labeled with 99mTc by adding 300 MBq
Na-99mTcO4 (Tyco Healthcare Mallinkrodt, Petten, The
Netherlands) to 10 μg of MB67 in the presence of 15 mg
tricine, 2 mg isonicotinic acid in 350 μl PBS, pH 7.0 and
25 μl SnSO4 (1 mg/ml) in 0.1N HCl. After incubation for
30 min at 100°C, quality control was performed using RP-
HPLC as described above.
After completion of the final PET image (4 h pi), all
rabbits were euthanized with a lethal dose of pentobarbital
(Euthesate, Ceva Sante Animale, Naaldwijk, The Nether-
lands) and the biodistribution of the 18F and 99mTc
radiolabels was determined as described previously [5,8].
The animal experiment was reviewed and approved by the
local animal welfare committee and performed in accordance
with Dutch governmental guidelines.
3. Results
3.1. Synthesis of [18F]FB
Direct [18F]-fluorination of p-trimethylammoniumben-
zaldehyde triflate using dried [18F]-fluoride cryptate was
complete within 10 min at 120°C. Purification of [18F]FB on
a combination of a cation-exchange cartridge (SCX) and a
reversed phase cartridge (C18) resulted in a product with a
radiochemical purity that always exceeded 95%. By elution
of immobilized [18F]FB from the C18 cartridge in reversed
direction and by fractionated collection of methanolic [18F]
FB from this cartridge, a high activity concentration was
obtained (2–4 MBq/μl). The overall synthesis time, includ-
ing purification, was 30 min with an overall decay corrected
radiochemical yield of between 65% and 85%.
3.2. Synthesis of [18F]-MB67 and PET imaging
[18F]-MB67 was obtained from the reaction of MB67
with [18F]FB at a maximum specific activity of 1200 GBq/
mmol. [18F]FB conjugated to MB67 proved to be stable: the
release of [18F]FB amounted to only 2% after 4 h of
incubation in PBS at 37°C.
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PET images of a rabbit with focal infection acquired at 2
and 4 h after injection of [18F]-MB67 are presented in Fig. 2.
The abscess was delineated already at 2 h pi, and the image
quality improved with time. The biodistribution of [18F]-
MB67 and [99mTc]-MB67 in rabbits as determined in
dissected tissues is shown in Fig. 3. For [18F]-MB67,
significantly lower values (Pb.05) for radioactivity uptake in
the abscess, spleen and liver were observed as compared to
its 99mTc-labeled counterpart, whereas radioactivity uptake
in the other organs showed no significant differences. The
obtained abscess-to-blood and abscess-to-muscle ratios were
not significantly different either.
4. Discussion
In the present study, an application of a new [18F]-
labeling methodology for [18F]-fluorination of hydrazine-
functionalized compounds is described. This fluorination
methodology is based on the reaction of an aldehyde, [18F]
FB, with a hydrazinonicotinic acid (HYNIC) functionalized
compound, forming a hydrazone bond. Chang et al. [2]
presented the first report on fluorination of a protein, human
serum albumin, using this methodology. The same metho-
dology was successfully used to fluorinate small peptides
such as c(RGDyK) [3], octreotide or substance-P [4] as well.
This is the first report on [18F]-fluorination of a nonpeptide/
protein compound, the LTB4 antagonist MB67, via hydra-
zone formation, and the first PET images are presented here.
[18F]-MB67 was obtained at a maximum specific activity
of 1200 GBq/mmol and was stable in PBS at 37°C for at least
4 h. PET imaging with [18F]-MB67 showed a clear
delineation of the infectious foci in rabbits and confirmed
the feasibility of the new [18F]-fluorination approach for in
vivo targeting. The in vivo biodistribution of [18F]-MB67
showed some similarity to that of [99mTc]-MB67, although
some differences were observed. Lower uptake of [18F]-
MB67 in abscess and spleen is most likely due to slight
differences in the physicochemical characteristics of [18F]-
MB67 as compared to [99mTc]-MB67. These differences
may reduce the ability of [18F]-MB67 to bind its receptors on
neutrophils. In [18F]-MB67, the fluorinated prosthetic group
is uncharged, whereas in its 99mTc-labeled counterpart the
99mTc-core with surrounding coligands is charged (Fig. 1).
The introduction of an additional benzyl group by binding of
[18F]FB to the HYNIC moiety of a compound results in a
more lipophilic product and this may have affected the
biological properties of the [18F]-fluorinated compound
negatively. In the case of [18F]-MB67, the lipophilicity
was counteracted by its eight hydrophilic cysteic acid
Fig. 3. Biodistribution at 4 h pi of the 18F-labeled leukotriene B4 receptor
antagonist MB67 and its 99mTc-labeled analog in rabbits with E. coli
infections (mean±1 S.E.M.). P b .05 (unpaired two-tailed t test). Comparison
of uptake of the two radiolabels in various organs, expressed as percentage
of the injected dose per gram of tissue (%ID/g, A) and a comparison of
abscess-to-blood and abscess-to-muscle ratios (B).
Fig. 2. Coronal posterior slices of PET images of a rabbit with an E. coli
abscess in the left thigh muscle at 2 and 4 h after injection of 40 MBq of the
[18F]-labeled leukotriene B4 receptor antagonist MB67. Arrows indicate the
site of infection.
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residues, but in the case of another relatively small
compound such as [18F]FB-octreotide, the increase in
lipophilicity was highly significant: the log value of the
octanol–water partition coefficient (log Po/w) of [
125I]
iodinated octreotide was minus 0.77±0.04 as compared to
1.49±0.09 for [18F]FB-octreotide [4]. Also, the reported
decrease in affinity of [18F]FB-HYNIC-c(RGDyK) as
compared to c(RGDyK) for αvβ3-integrin might be
explained by the presence of two additional lipophilic
aromatic systems in the HYNIC and [18F]FB moieties of
[18F]FB-HYNIC-c(RGDyK) [3].
The specific activity of the [18F]-MB67 preparation used
was much lower than that of the 99mTc-labeled product:
100 μg of [18F]-MB67 was injected per rabbit as opposed to
only 3 μg of [99mTc]-MB67. Hydrazone formation is favored
by high concentrations of the hydrazine-containing com-
pound. However, [18F]FB is a highly volatile compound and
cannot be easily concentrated before reaction with MB67. A
relatively high amount of MB67 had to be added in order to
obtain a reasonable labeling efficiency. As a consequence of
a modest specific activity of [18F]-MB67, receptor saturation
due to the higher dose of unlabeled MB67 could have
occurred. Although specific abscess uptake was demon-
strated with the fluorinated compound, the relatively low
specific activity may limit the application of this [18F]-
labeling approach. The relatively low specific activity of a
[18F]-labeled tracer could result in reduced uptake in the
target tissue due to receptor saturation. Furthermore, the
relatively high dose of the radiotracer could induce
pharmacological effects. In our case, pharmacologic effects
were not observed after administration of 100 μg [18F]-
MB67 per rabbit, which is in line with our previous
observation that administration of a dose as high as 2 mg
of LTB4 antagonist in rabbits does not result in significant
changes in white blood cell counts [11].
Furthermore, this approach can only be applied to
receptor binding ligands of which the pharmacokinetics
match the physical half-life of 18F (108 min). In the case of
[18F]-MB67, PET imaging of infection was feasible at 2 h pi,
but imaging at 4 h pi resulted in higher uptake in the abscess
and higher abscess–background ratios. The kinetics of
MB67 match better with 99mTc (physical half-life of 6 h)
than with 18F.
The use of [18F]-MB67 may offer distinct advantages over
that of its 99mTc-labeled counterpart, in particular applica-
tions where the enhanced resolution of PET (and PET-CT)
imaging could be exploited, e.g., in colitis, appendicitis and
endocarditis (especially in combination with CT).
5. Conclusion
In the present study, we demonstrated the feasibility of the
[18F] hydrazone formation strategy for PET imaging of
infection using an LTB4 antagonist. This study confirms the
use of HYNIC-functionalized precursors for [18F]-labeling
besides its use for 99mTc-labeling. At this point the approach
has a few limitations: (1) the specific activity of the tracer is
relatively low; (2) fluorination with this method enhances the
lipophilicity of the tracer; (3) application of this approach is
restrained to tracers with fast pharmacokinetics. Despite its
limitations, this approach offers a new way to label (non)
peptides with 18F for various applications in PET. Further
research is warranted to optimize this versatile fluorination
strategy to obtain a tracer with a higher specific activity to
broaden the application of this method.
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